SCSjors F. P. J. Coppus

Sjors F. P. J. Coppus

*This is an algorithmically generated author record based on publicly available information.

Sjors F. P. J. Coppus has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of the clinical and cost-effectiveness of transcervical ultrasound-guided radiofrequency ablation of leiomyomas (ESONATA): a prospective comparative cohort study

    by Tessel H. Cooijmans, Zoë Dujardin, Julia F. van der Meulen, Peggy M.A.J. Geomini, Sjors F.P.J. Coppus, Carolien A.M. Koks, Jaklien C. Leemans, Marlies Y. Bongers


  • Open Access

    Comparing Methods to Determine Complete Response to Chemoradiation in Patients with Locally Advanced Cervical Cancer

    by Kim van Kol, Renée Ebisch, Maaike Beugeling, Jeltsje Cnossen, Joost Nederend, Dennis van Hamont, Sjors Coppus, Jurgen Piek, Ruud Bekkers

    Objectives: There is no consensus on the most reliable procedure to determine remission of cervical cancer after chemoradiotherapy (CRT). Therefore, this study aims to assess the diagnostic performance of two different imaging techniques, MRI and 18F[FDG]-PET/CT, in determining the presence of locoregional residual disease after CRT in patients with locally advanced cervical cancer. Methods: Patients diagnosed with locally advanced cervical cancer (FIGO 2009) treated with CRT were retrospectively identified from a regional cohort. The accuracy of MRI and 18F[FDG]-PET/CT in detecting locoregional residual disease was assessed with histology as the reference standard. Results: The negative predictive value (NPV) and positive predictive value (PPV) for locoregional residual disease detection of MRI and 18F[FDG]-PET/CT combined were 84.2% (95% CI 73.2–92.1), and 70.4% (95% CI 51.8–85.2), respectively. The NPV and PPV of MRI alone were 80.2% (95% CI 71.2–87.5) and 47.7% (95% CI 35.8–59.7), respectively, and values of 81.1% (95% CI 72.2–88.3) and 55.8 (95% CI 42.2–68.7), respectively, were obtained for 18F[FDG]-PET/CT alone. Conclusion: In this study, the reliability of MRI and 18F[FDG]-PET/CT in detecting locoregional residual disease was limited. Combining MRI and 18F[FDG]-PET/CT did not improve predictive values. Routine use of both MRI and 18F[FDG]-PET/CT in the follow-up after CRT should be avoided. MRI during follow-up is the advised imaging technique. Pathology confirmation of the presence of locoregional residual disease before performing salvage surgery is warranted.


  • Procedural sedation and analgesia with propofol (PSA) for gynecologic surgery: A systematic review of the literature

    by Julia F. van der Meulen, Charlotte Fisch, Janique R.J. Dreessen, Sjors F.P.J. Coppus, Helen S. Kok, Marlies Y. Bongers


  • Open Access

    The (cost) effectiveness of procedural sedation and analgesia versus general anaesthesia for hysteroscopic myomectomy, a multicentre randomised controlled trial: PROSECCO trial, a study protocol

    by Julia F. van der Meulen, Marlies Y. Bongers, Sjors F. P. J. Coppus, Judith E. Bosmans, José M. C. Maessen, Katrien Oude Rengerink, Lucilla E. Overdijk, Celine M. Radder, Lucet F. van der Voet, Nicol A. C. Smeets, et al.

    In women with abnormal uterine bleeding, fibroids are a frequent finding. In case of heavy menstrual bleeding and presence of submucosal type 0–1 fibroids, hysteroscopic resection is the treatment of first choice, as removal of these fibroids is highly effective. Hysteroscopic myomectomy is currently usually performed in the operating theatre. A considerable reduction in costs and a higher patient satisfaction are expected when procedural sedation and analgesia with propofol (PSA) in an outpatient setting is applied. However, both safety and effectiveness – including the necessity for re-intervention due to incomplete resection – have not yet been evaluated. This study is a multicentre randomised controlled trial with a non-inferiority design and will be performed in the Netherlands. Women > 18 years with a maximum of 3 symptomatic type 0 or 1 submucosal fibroids with a maximum diameter of 3.5 cm are eligible to participate in the trial. After informed consent, 205 women will be randomised to either hysteroscopic myomectomy using procedural sedation and analgesia with propofol in an outpatient setting or hysteroscopic myomectomy using general anaesthesia in a clinical setting in the operating theatre. Primary outcome will be the percentage of complete resections, based on transvaginal ultrasonography 6 weeks postoperatively. Secondary outcomes are cost effectiveness, menstrual blood loss (Pictorial blood assessment chart), quality of life, pain, return to daily activities/work, hospitalization, (post) operative complications and re-interventions. Women will be followed up to one year after hysteroscopic myomectomy. This study may demonstrate comparable effectiveness of hysteroscopic myomectomy under procedural sedation and analgesia versus general anaesthesia in a safe and patient friendly environment, whilst achieving a significant cost reduction. Dutch trial register, number NTR5357 . Registered 11th of August 2015.